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Background: The aim of this study is to compare the 12-year follow-up effects on in- and outpatient services of
2 years of integrated treatment for recent-onset schizophrenia versus treatment as usual in a randomized controlled
trial.
Methods: 50 patients aged 18–35 years were randomized to Integrated Treatment (IT) (N = 30) or Treatment-as-Usual
(TAU) (N = 20) for two years. TAU comprised optimal pharmacotherapy and outreach assertive treatment, while IT also
included cognitive-behavioural family treatment, skills training, strategies for residual psychotic and non-psychotic
problems and home-based crisis management.
Results: There were no differences in number of days in hospital, time to readmission, number of admittances to
psychiatric wards, number of involuntarily psychiatric admissions or number of outpatient contacts over a period of
12 years following the initial 2-year treatment trial. Fewer patients in the IT group were, however, involuntary admitted
to hospital in the period.
Conclusions: The intensive two-year psychosocial intervention seemed to have little long-term effects on use of
in- and outpatient services.
Trial registration: Current Controlled Trials: NCT00184509
Keywords: Schizophrenia, Integrated treatment, Early intervention, Long term outcomeBackground
Increased focus on the importance of early interventions
in psychosis, with initiation of treatment during the
“critical period”, has led to the development of time-
limited specialized early interventions [1,2]. The aims of
these early specialized treatments are to shorten the dur-
ation of untreated psychosis, preventing relapses and
thereby improving prognosis [3,4].
There are three different early intervention approaches;
1) interventions focusing on recognizing and helping young
individuals at high risk of developing psychosis (i.e., before
debut of psychosis); 2) early identification programs where
the goal is to identify and treat patients in the very* Correspondence: vidir.sigrunarson@ntnu.no
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distribution, and reproduction in any mediumbeginning of the first psychotic episode, and 3) specialized
services to patients with recent but established psychosis
[1,5].
Randomized controlled trials (RCT) have shown
promising effects of early specialized interventions on
short term outcomes (reduction in hospital admissions
and symptoms and improved function) or as long as the
treatment continues [6-8]. Furthermore, early interven-
tions in psychosis have been found to be cost effective
compared to standard care [9].
The long-term effects of these treatments are, how-
ever, still unclear. In a review of outcomes at 3–5 years
after early psychosis intervention, Bird et al. concluded
that it is undetermined if the effects of early interventions
are sustainable [2]. Except from indications of improved
social outcomes, recent findings from 5-year follow-up
studies have shown low effects on admission rate and
mean number of bed days [10], level of psychotic andntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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abuse, depression, and suicidal behaviour [12].
The aim of this study was to compare the long-term
effects of 2 years of integrated treatment (IT) for recent-
onset psychosis versus treatment as usual (TAU) in a
randomized controlled trial. Firstly we hypothesized that
integrated treatment would have long-term effects on
number of days in hospital during the 12–year follow-up
period. Hence, we also hypothesized that patients receiv-
ing integrated treatment would have reduced number of
psychiatric admissions; number of outpatient psychiatric
contacts, use of involuntary admissions, duration of inpa-
tients and outpatient involuntary treatment, and mortality.
To our knowledge this is the first long-term RCT
reporting a follow up on outcome 14 years after initi-
ation of treatment.
Methods
The present study was a centre in the International
Optimal Treatment multi-site project initiated by Dr. Ian
R.H. Falloon in 1994. The aim was to evaluate the effects
of applying evidence-based integrated biomedical and
psycho-social interventions in routine services for patients
with recent-onset and chronic schizophrenia and other
non-affective psychotic disorders [13]. The present study
is based on the original RCT [6].
Participants
From 1992 to 1997 at the St. Olav’s University Hospital
in Trondheim, Norway, 50 consecutive patients with re-
cent onset psychosis, referred to a specialized team for
treatment of psychosis, were included in a RCT compar-
ing IT and TAU. Recent onset was defined as having ex-
perienced their first symptoms of psychosis within the
last two years before inclusion.
Clinically stable patients between 18–35 years, diag-
nosed with DSM-IV [14] schizophrenia, schizoaffective or
schizophreniform disorders by a psychiatrist or a clinical
psychologist trained to administer the Structured Clinical
Interview for the DSM-IV, were invited to participate in
the study. Patients with mental retardation, substance use
disorders or who were not expected to reside in the
county for at least one year after inclusion, were excluded.
30 patients were randomly allocated to two years of inte-
grated psychosocial treatment (IT) and the remaining 20
were provided treatment-as-usual (TAU).
Prior to randomization to IT or TAU written informed
consent was obtained and an independent assistant com-
pleted baseline assessments [6,15,16].
The mean age of the patients (30 men and 20 women)
at admission was 25.4 (SD 4.6) years (Table 1), whereas
the mean age at the end of follow-up was 39.0 (SD 4.6)
years. At study entry the diagnoses (DSM-III-R; American
Psychiatric Association, 1987) were: schizophrenia, 40(80%); schizoaffective disorder, 6 (12%); and schizophre-
niform disorders, 4 (8%).
The research was carried out in compliance with the
Helsinki Declaration and the study was approved by The
Regional Committee for Medical and Health Research
Ethics in Central-Norway.
Interventions
All participants received TAU which included regular
out-patient case management with antipsychotic medica-
tion, crisis in-patient treatment when needed, supportive
housing and day care, rehabilitation promoting work ac-
tivities and independent living, supportive psychotherapy
and brief psycho-education.
IT was based on methods described in published man-
uals [17,18] and was comparable to what was reco-
mmended as optimal treatment for schizophrenia in
international guidelines at the time. In addition to TAU,
IT patients were treated by a multi-disciplinary team inde-
pendent of the TAU program. The caseload in the IT-
team was low with patient staff ratio approximately 1 to
10. IT patients and their primary caregivers received cog-
nitive–behavioural family communication and problem
solving skills training, individual cognitive-behavioural
strategies for residual symptoms and disability and struc-
tured single-family psycho-education. Education in use of
medication and methods to improve medication adher-
ence was given [13].
Most patients received weekly treatment-sessions during
the first 2 months and then at least one treatment-session
every third week during the first year. The second year of
the project treatment-sessons were provided at least once
each month. In periods of crisis and excercebations assert-
ive out-reach crisis management was provided at home up
to 3 hours per week, often supplemented with phone-
consultations. For those patients who had limited contact
with any informal caregivers, about 20%, family education
and problem solving sessions were given as individual
treatment-sessions. [6,15,16].
At the end of the 2 years treatment period participants
from the IT group were transferred to treatment as usual.
Outcomes
The primary follow-up outcome was the number of days
in hospital during the 12 year follow-up period. Secondary
objectives were number of psychiatric admissions, number
of outpatient psychiatric contacts, use of involuntary ad-
missions, duration of inpatient and outpatient involuntary
treatment, and mortality.
Randomization
Patients were randomly allocated to IT or TAU using a
sequence of sealed pre-numbered envelopes with group
assignments according to random numbers provided by
Table 1 Demographic and clinical characteristics for the integrated treatment (IT) and treatment as usual (TAU) groups
at baseline
Variables All patients
(n = 45)
IT group
(n = 28)
TAU group
(n = 17)
Statistics P-value
Baseline demographics
Age. Mean (SD) 24.5 (4.5) 25.5 (4.8) 24.3 (4.2) Independent t-test .395
Gender. No. (%)
Female 18 (40) 11 (39) 7 (41) Chi-Square .900
Male 27 (60) 17 (61) 10 (59)
Hospitalized before study entry. No (%)
Yes 39 (87) 27 (96) 12 (71) Fishers Exact test .023*
No 6 (13) 1 (4) 5 (29)
Days hospitalized 12 months preceding study entry. Mean (SD) 131 (103) 131 (105) 131 (103) Independent t-test .983
Psychiatric assessments, baseline.
Diagnoses (DSM-IV). No. (%)
Schizophrenia 40 (80) 23 (76) 17 (85)
Schizoaffective 6 (12) 5 (17) 1 (5)
Schizophreniform 4 (8) 2 (7) 2 (10)
GAF score. Mean (SD) 49.7 (10.7) 52.0 (11.5) 45.9 (8.3) Independent t-test .064
Total BPRS score. Mean (SD) 39.7 (7.6) 37.9 (7.5) 42.6 (7.2) Independent t-test .046*
Antipsychotic drugs, Chlorpromazine equivalent dose per day (mg). Mean (SD) 229 (118) 211 (93) 259 (148) Independent t-test .185
*significant difference.
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tion. A secretary outside the clinical services opened the
envelopes. Gender was stratified in blocks of varying size
(between 8 and 12 and with a ratio of 3:2 of IT to TAU)
ensuring that a majority of the patients received the ex-
perimental treatment [6]. Case recruitment, allocation
and retention are summarized in Figure 1.Results from initial study
It has earlier been reported that IT was associated with
greater reductions in negative symptoms, minor psychotic
episodes, and in stabilising positive symptoms. The pro-
portion of cases with excellent two-year clinical outcomes
doubled, but 47% of cases remained in need of continuing
treatment for their persisting symptoms and/or disability,
or risk of recurrence. No effect on adherence to medica-
tion was found [6,15,16].Follow-up study
In 2011 and 2012 the participants of the study were asses-
sed over a period of 12 years following completion of the
initial 2-years intervention (i.e., 14 years after study entry).
Data on hospital admissions, involuntary in- and out-
patient treatment, out-patient contacts and mortality
(1992–2011) were obtained from the official Patient
Administrative System, a standard system for clinical
data in the health trust.Data were cross-checked with and verified through
scrutiny of the medical records. Data were assembled for
each participant from the date of randomization to inter-
vention and 14 years forward. The 12-year follow-up
covered a period beginning 2 years after randomization.Statistics
Categorical variables were analysed using Chi-squared
tests. Continuous variables were analysed using Student’s
t-test. A log rank test was used to compare the survival
time distribution before re-hospitalization of the two
groups. The α-level was set to 0.05. SSPS version 18 was
used for statistical analysis. The statistical tests for the
outcome variables are listed in Table 2.Results
Participants flow
In the two-year IT intervention period, five patients had
reduced treatment participation and retention. Four
TAU patients received very limited follow-up and psy-
chosocial treatment. All participants were included in
the assessments in the two-year intervention period.
In the long-term follow-up study complete data on 45
of the 50 patients were accessible from hospital records.
Five patients had migrated from the region (two from
the IT group). One patient from the control group died
four years and nine months into the follow-up period.
Assessed for 
eligibility (n = 
168)
Excluded (n = 46)
Not recent onset (n=21)
Substance abuse (n=4)
Lived outside catchment area (n=4)
No written consent (n=4)
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Not recovered from initial psychotic 
episode (n=11)
DSM – IV 
schizophrenia (n = 
96)
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(n=27)
Received little 
or no treatment 
(n=3)
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(n=16)
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Participants followed up (n=17) (85 % of original 
cohort). One patient died four years and nine 
months into follow-up period.
Participants 
followed up 
(n=28) (90 % of 
original cohort)
Randomized
(n=50)
Figure 1 Participant flow.
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the 12-year follow-up.
Outcome measures are summarized in Table 2. There
was a significant group difference in number of patients
involuntary admitted to hospital during the follow-up
period (p = .042, phi = .30). No other significant differ-
ences were found between the IT and TAU groups. An
analysis of covariance (ANCOVA) controlling for days
hospitalized 12 months preceding study entry, showed
no significant difference between the IT and the TAU
group in mean days hospitalized during 12 years follow-
ing treatment trial. (p = .761).
In the IT group 12 were frequent users (more than
100 inpatient days during follow up period) of these six
were extensive users (more than 500 inpatient days). In
the TAU group 12 were frequent users (ns), four of theseextensive users (Table 3). There was one death in the
TAU group due to complications following suicide
attempt.
A log rank test comparing the survival time distribu-
tions before readmission of the two groups showed no
significant differences on time to readmission between
the IT and TAU groups (Χ2 = 2.055, df = 1, p= > .05). A
Kaplan-Meier survival curve is shown in Figure 2. The
mean time (95% CI) to readmission for the IT group was
2 474 days compared to 1 687 days for the TAU group.Discussion
To our knowledge this is the first long term RCT follow-
up (12 years) study on intensive Integrated Treatment
for patients with recent-onset schizophrenia.
Table 2 Twelve year follow-up: use of psychiatric services, coercion and suicides among patients with Integrated
Treatment (IT) and Treatment As Usual (TAU)
All (n = 45) IT (n = 28) TAU (n = 17) Statistics Chi Square -/ t-value P-value
Admitted to psychiatric wards. No. (%) 28 (62) 15 (54) 13 (77) Chi-Square 2.36 0.125
Time to first readmission. Mean (SE) 2177 (277) 2474 (356) 1687 (414) Log rank 2.06 0.152
Days as inpatient. Mean (SD) 385 (591) 364 (610) 420 (574) t-test −310 0.758
Involuntary admitted. No. (%) 23 (51) 11 (39) 12 (71) Chi-Square 4.15 0.042*
No. of admissions as inpatient. Mean (SD) 5.0 (7.2) 4.4 (7.9) 6.0 (5.9) t-test -.740 0.463
Frequent users: 100–500 inpatient days. No. (%) 14 (31) 6 (21) 8 (47) Chi-Square 3.27 0.072
Extensive users: more than 500 inpatient days. No. (%) 10 (22) 6 (21) 4 (24) Chi-Square .03 0.869
Psychiatric outpatient follow-up. No. (%) 44 (98) 28 (100) 16 (94) Chi-Square 1.68 0.194
No. of psychiatric outpatient visits. Mean (SD) 107 (109) 114 (110) 96 (110) t-test .540 0.592
Suicides. No. 1 0 1 - - -
Outpatient coercion. No. (%) 14 (31) 8 (29) 6 (35) Chi-Square .22 0.637
Days involuntary admitted. Mean (SD) 263 (525) 265 (591) 259 (413) t-test .033 0.974
Days outpatient coercion. Mean (SD) 252 (511) 221 (463) 305 (594) t-test -.528 0,600
Total days under coercion. Mean (SD) 515 (945) 486 (962) 564 (943) t-test -.266 0.791
No. number, SE standard error, SD standard deviation, * = significant difference.
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tients in the IT group and 12 of 17 in the TAU group)
were involuntary hospitalized. This is an important
finding and should have implications in planning of ser-
vices for patients with schizophrenia. There were, how-
ever, no difference in the number of days they were
involuntary admitted. No significant differences were
found between groups receiving integrated treatment or
treatment-as-usual with respect to number of inpatient
days, number of patients admitted to psychiatric wards,
number of admissions to psychiatric wards, use of out-
patient coercion or number of outpatient contacts over
a period of 12 years. Although median time to readmis-
sion was considerably longer for the IT group, this dif-
ference did not reach statistical significance (possibly
because of the sample size). Given that no effects on
hospitalization were found in the first two years, these
findings might not be surprising and limited conclu-
sions can be drawn given that only 45 patients were in-
cluded in the analyzes.Table 3 Inpatient days during 12 years follow-up period
divided according to extent of use
No. of
inpatient
days
No. of
patients
(%)
Total no. of
inpatient days
(%)
Percent of total
inpatient days per
patient
0 17 (38) 0 (0.0) 0.0
1–100 days 4 (9) 273 (1.6) 0.4
100–
500 days
14 (31) 3949 (22.8) 1.6
>500 days 10 (22) 13104 (75.6) 7.6
N = 45.The findings are in line with other recent studies on
3–5 year outcomes reporting that time-limited early spe-
cialized interventions for schizophrenia do not improve
outcome over time [10,11].
This lack of significant long-term effects on the use of
services may be understood in several ways. Time-
limited evidence- based psychosocial and pharmaco-
logical interventions do alleviate the present suffering
from the illness, but may not change or hamper the
long-term course of the illness [19]. It is, however, pos-
sible that there are long-term effects of such interven-
tions, but that such effects only applies to subgroups of
patients responding to elements of the interventions
[5]. It is interesting that 10 of the 45 patients in this
study counted for 76% of all inpatient days during the
12-year follow-up period. This group of patients with
schizophrenia with extensive use of psychiatric services
may represent a group which needs special attention
and could potentially gain much from long term stan-
dardized care.
In the original study, IT had a beneficial impact on
negative symptoms, minor psychotic episodes, and sta-
bilizing positive symptoms [6]. In modern psychiatric
care, improvements in negative symptoms might reduce
the need for community services more than reduce the
need for hospital admissions.
In this study the participants had recent-onset but
established psychosis. The majority (87%) entered the
study after their first hospitalization and had been hospi-
talized on average over 100 days before inclusion.
It is possible that integrated interventions at an earlier
stage could have improved their long-term use of ser-
vices. Such an assumption is supported by the results
Figure 2 Survival curves for time to readmission after
termination of 2 years of treatment trial. IT: Integrated treatment,
TAU: treatment as usual. Log rank: P = 0.152.
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study where early detection and intervention of recent
onset schizophrenia improved 10 year outcomes [20,21].
In this study the patients in both the experimental and
the control group received early intervention treatment.
The difference was that those in the experimental group
received this treatment significantly earlier then the con-
trols (shorter duration of untreated psychosis). Support
for the effects of even earlier interventions comes from a
recent meta-analysis on “risk of transition to psychosis”
among persons with high risk for psychosis. This study
suggests that transition into psychosis among high risk
persons may be reduced by cognitive therapy and anti-
psychotic medications [22].
Yet another explanation for the lack of long-term effects
on the use of services of the early integrated treatment
demonstrated in our study is that the treatment was too
time-limited. The effects of early interventions during the
treatment period have been proven through multiple tri-
als. Long-term continuous interventions may be needed if
clinically significant effects are to be sustained. In the Pre-
vention and Early Intervention Program for Psychoses in
London, Ontario, long-term symptom improvements were
obtained after providing the patients with five years con-
tinued, albeit less intensive, specialized treatment [23].
Involuntary admissions remain a controversial medical
procedure associated with ethical dilemmas and patients
with schizophrenia are among those most often involun-
tary admitted [24]. Research show that involuntarytreatment is associated with more severe illness, reduced
treatment motivation and less insight [25].
Reduction in the use of involuntary admissions is an
important treatment goal. Our results suggest that long-
term reduction in involuntary admissions of patients
with schizophrenia is attainable by providing early inte-
grated treatment. Forced admissions are not only a re-
sult of symptom exacerbations, but may be associated
with other psychosocial variables as insight [26], violence
and adherence to psychosocial treatment [27]. It is
therefore possible that the group difference in forced ad-
missions could be explained by variety of such other as-
pects of the illness. Components of the IT such as
cognitive–behavioural family communication and prob-
lem solving skills training, individual cognitive-
behavioural strategies for residual symptoms and disabil-
ity have many similarities to a “crisis plan” which is a
psychiatric intervention aimed specifically at reducing
use of coercive measures [28]. A RCT on the use of cri-
sis plans found a significant reduction in use of involun-
tary admissions [29]. This was not associated with
differences in overall admissions, as is the case in our
finding.
Use of in- and outpatient services is only one of many
factors used as outcome measure in schizophrenia. Recov-
ery in schizophrenia is a complex and multi-dimensional
concept encompassing both objective and subjective out-
come dimensions [30] and an ongoing change progress
[31]. Objective outcome dimensions include symptom re-
mission, employment, housing and relations to others
while subjective outcome dimensions include appraisal of
life circumstances and self-appraisal. Because of the lim-
ited scope of outcome measures in this study the possible
long-term effects of IT on these multiple aspects of recov-
ery may be hidden and not revealed.
Data from one patient in the TAU group who died
4 years and 9 months into the follow-up period were in-
cluded in the statistical analyses and no statistical correc-
tions were made to make up for the lack of data for the
remaining period. As this patient died of suicide, which is
the worst possible clinical outcome, it would be likely that
this patient’s long-term clinical outcome would have been
poor if the patient had lived. Therefore the inclusion of
this patient’s data in the analyses may somewhat have
influenced the results for the TAU group.
Limitations
A sample size of 45 is too low to reveal reliable differ-
ences between the two treatment groups. Only a large
sample size or a large effect size would be sufficient to
test the hypothesis that the groups do not differ on
number of days as in-patients or number of admittances
as in-patients. P-values between 0.01 and 0.05 should be
interpreted with caution, because of multiple analyses.
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data from psychiatric in- and outpatient services.
Whether all psychiatric admissions and outpatient treat-
ment periods were attributable to psychotic illness can-
not be ascertained.
Another possible source of bias was that the researchers
were not blinded or prevented from knowing which group
the patients belonged to. However, because the outcome
data were based upon objective information on dates and
number of incidences, and because the admission data
were collected for clinical and legal purposes (and not as a
part of the study), the risk of information bias is consid-
ered to be minimal.
Use of in- and outpatient services may not be an opti-
mal measure of outcome in schizophrenia and other as-
pects of recovery should also be considered. Clinically
unstable patients and patients with substance abuse were
excluded from the study and this possibly reduces the
generalizability of the study.
Despite these shortcomings this is the first RCT covering
a follow-up period of 12 years. This is considered to be im-
portant information for clinical practice. The long observa-
tion period and the possibility to get complete data from
90% of the participants are major strengths in the study.
Clinical implications
The findings of this long term follow-up study, on the ef-
fects of integrated treatment for recent onset psychosis, fur-
ther strengthen the implications from other recent studies
that the short-term effects of early time-limited integrated
treatment may not be sustainable. We found that involun-
tary treatment of patients with schizophrenia can possibly
be prevented with early integrated treatment efforts.
Our findings must be replicated before any conclu-
sions can be drawn about the effect of IT on long-term
use of in- and outpatient services.
Future research
RCTs on long-term effects of interventions including
early identification and continuous integrated treatment
for schizophrenia, focusing on different aspects of recov-
ery, are needed.
Psychological treatments for schizophrenia as a whole
are emerging and of potential importance for future
studies are the effects of emerging integrative forms of
psychotherapy.
It is also important to gain more knowledge about
how poor and good outcome schizophrenia can be iden-
tified at an early stage of the illness in order to optimize
the allocation of health resources.
Conclusion
The intensive two-year psychosocial intervention seemed
to have little long-term effects on use of in- and outpatientservices. Significantly fewer patients receiving IT were in-
voluntary hospitalized during the follow up period.
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